Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)
CINCINNATI, Jul 06, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2005. This index is made up of 314 stocks composed of U.S. companies with the most consistent records of annual dividend increases.
Quoting from Mergent's press release, "Dividend Achievers represent the elite of the U.S. stock market. These are generally well known companies that as a group have been shown to consistently outperform the overall market." The press release went on to comment, "Not only do these companies represent the very best of U.S. stocks, but as a group they offer a relatively low-risk investment and of course there are significant tax breaks that further increase the potential yield to the ordinary investor."
William J. Motto, Chairman and Chief Executive Officer, stated, "We are very pleased to have been added to the Mergent's Dividend Achievers Index(TM) for the second year in a row. Our long-standing cash dividend policy has served shareholders well with thirteen increases during the past fifteen years. Our current indicated annual cash dividend rate is $0.48 per share. With our strong cash flow from operations, we are able to internally fund the company's growth and concurrently payout between 75% and 85% of our net earnings in cash dividends to shareholders."
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, and respiratory infections. Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company's shares are traded through Nasdaq's National Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
SOURCE: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700